Organon & Co (STU:7XP)
€ 14.33 0.38 (2.72%) Market Cap: 3.72 Bil Enterprise Value: 11.38 Bil PE Ratio: 2.99 PB Ratio: 7.87 GF Score: 67/100

Organon & Co at Cowen Health Care Conference (Virtual) Transcript

Mar 09, 2022 / 02:10PM GMT
Release Date Price: €33.7 (-3.85%)
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning, and welcome to the Organon session of Cowen's 42nd Annual Healthcare Conference. We're very pleased to have with us the top management of Organon, one of the most unique and exciting and emerging companies in the biopharma space. So we're very pleased to have you with us at our conference.

Representing the company is Kevin Ali, who is the CEO; Matthew Walsh, who is the CFO; Sandra Milligan, who is the Head of R&D; and Jen Halchak, who is the Head of Investor Relations.

Questions & Answers

Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

So with that, I'd like just to dive right into the Q&A. We'll centermost of the companies on the women's health area -- most of the questions on the women's health area, but we may sprinkle in a few others as well.

So let's start out with your most important product, that being NEXPLANON. Q4 for NEXPLANON was the highest quarter

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot